Thirty years ago, few of us could have envisioned today’s practice of aesthetic medicine. Led by botulinum toxin type A (BoNTA), innovation in facial injectables has revolutionized our practices. New technologies are poised to further expand aesthetic treatment opportunities in the near future. To fuel continued progress, regulatory bodies must accurately reflect the knowledge and best practices shaped from the research and experience of the past 3 decades.
Aesthetic medicine is unique; clinical success is inextricably linked to patient perception and preference. Whereas eradication of acne lesions or squamous cell carcinomas is easily quantified in medical dermatology, optimal outcomes in aesthetic medicine are not as objectively defined.
Glogau R, Biesman B, Kane M. Assessment of Botulinum Toxin Aesthetic OutcomesClinical Study vs Real-World Practice. JAMA Dermatol. 2015;151(11):1177-1178. doi:10.1001/jamadermatol.2015.2881